Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
94.00K | 306.00K | 268.00K | 82.00K | 25.00K | 36.00K | Gross Profit |
-736.00K | 96.00K | 75.00K | 45.00K | 14.00K | 18.00K | EBIT |
-35.94M | -39.82M | -45.65M | -35.40M | -17.97M | -16.56M | EBITDA |
-31.24M | -35.29M | -42.91M | -33.60M | -17.11M | -13.60M | Net Income Common Stockholders |
-32.24M | -36.24M | -44.25M | -36.23M | -21.61M | -20.44M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
21.39M | 49.08M | 82.70M | 105.11M | 13.53M | 21.39M | Total Assets |
0.00 | 95.44M | 116.33M | 147.03M | 14.80M | 23.26M | Total Debt |
0.00 | 1.86M | 2.31M | 128.00K | 8.67M | 9.31M | Net Debt |
21.39M | -2.02M | -27.57M | -58.80M | -4.86M | -12.07M | Total Liabilities |
0.00 | 25.28M | 17.39M | 8.46M | 140.37M | 129.88M | Stockholders Equity |
10.96M | 70.16M | 98.94M | 138.56M | -125.57M | -106.62M |
Cash Flow | Free Cash Flow | ||||
-15.75M | -27.32M | -35.40M | -32.94M | -17.02M | -19.43M | Operating Cash Flow |
-14.69M | -27.19M | -34.61M | -31.64M | -16.87M | -19.32M | Investing Cash Flow |
4.73M | 438.00K | 5.55M | -82.56M | -149.00K | -6.00K | Financing Cash Flow |
2.99M | 752.00K | 5.00K | 159.59M | 9.16M | 33.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $130.26M | ― | -117.50% | ― | 1.78% | 22.46% | |
55 Neutral | $106.91M | ― | -1552.23% | ― | 25.46% | 21.83% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
52 Neutral | $50.58M | ― | 138.92% | ― | 64.15% | 41.65% | |
46 Neutral | $146.18M | ― | -91.03% | ― | -40.09% | -18.67% | |
46 Neutral | $39.69M | ― | -1454.41% | ― | 35.76% | 47.48% | |
43 Neutral | $79.87M | ― | -41.36% | ― | -44.17% | 12.77% |
On May 8, 2025, Sera Prognostics announced the appointment of Lee Anderson as Chief Commercial Officer, marking a strategic move to enhance its commercial expansion and innovation. Anderson, with over 30 years of experience in the healthcare sector, is expected to drive the adoption and sales of Sera’s PreTRM Test, leveraging his successful track record from previous roles at Genomic Health and Exact Sciences. His leadership is anticipated to strengthen Sera’s market presence and support its mission to transform women’s healthcare.